newsfilter
← Latest News
PR Newswire·

Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022

HAYWARD, Calif., April 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,